PLBIO: The net profit for the third quarter was 121 million yuan, a decrease of 43.74%Zhitong·Oct 28, 2025 at 05:18 AM000403+0.10%
Open Source Securities: API companies accelerate the layout of innovative drugs, and the AI + medical layout is gradually deepeningZhitong·Sep 24, 2025 at 09:30 PM688185+1.43%06185+0.43%
PLBIO released its performance for the first half of the year, with a net profit attributable to the parent company of 236 million yuan, a decrease of 27.89%Zhitong·Aug 21, 2025 at 09:16 AM000403+0.10%
BTBP plans to abandon the acquisition of PLBIO business opportunityZhitong·Aug 4, 2025 at 04:18 AM000403+0.10%6001610.00%
The biopharmaceutical sector saw a short-term surge, with BTBP hitting the daily limitZhitong·Aug 4, 2025 at 12:59 AM000403+0.10%6001610.00%
The biopharmaceutical sector sees a short-term surge, PLBIO hits the limit upZhitong·Jun 12, 2025 at 12:05 AM688180+2.15%01877+0.22%
PLBIO's ownership change confirmed by China National Biological Group, further concentration of blood products achieves another milestoneWallstreetcn·Jun 9, 2025 at 10:12 AM000403+0.10%
PLBIO: The controlling shareholder plans to change to China National Biological, and the stock will resume tradingZhitong·Jun 9, 2025 at 07:21 AM000403+0.10%
PLBIO plans to increase 3 shares for every 10 shares and distribute 3.5 yuan on June 4th, ex-rights and ex-dividendZhitong·May 26, 2025 at 06:26 AM000403+0.10%
PLBIO received the administrative supervision measures decision from the Shanxi Securities Regulatory BureauZhitong·May 11, 2025 at 03:42 AM000403+0.10%
PLBIO released its first-quarter performance, with a net profit attributable to the parent company of 89.0892 million yuan, a year-on-year decrease of 26.95%Zhitong·Apr 23, 2025 at 10:41 AM000403+0.10%
PLBIO has obtained approval for clinical trials of intravenous human immunoglobulin (10%) for new indicationsZhitong·Apr 7, 2025 at 03:04 AM000403+0.10%
